Stifel on C4 Therapeutics (CCCC): 'we still think more context is needed for it to be a stock catalyst'
Tweet Send to a Friend
Stifel analyst Bradley Canino reiterated a Buy rating and $14.00 price target on C4 Therapeutics (NASDAQ: CCCC).The analyst comments "First ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
